This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...